Literature DB >> 19544399

Differentiation of synovial CD-105(+) human mesenchymal stem cells into chondrocyte-like cells through spheroid formation.

M C Arufe1, A De la Fuente, I Fuentes-Boquete, Francisco J De Toro, Francisco J Blanco.   

Abstract

Mesenchymal stem cells (MSCs) have the capacity to differentiate into several cell lineages, some of which can generate bone, cartilage, or adipose tissue. The presence of MSCs in the synovial membrane was recently reported. Data from comparative studies of MSCs derived from various mesenchymal tissues suggest that MSCs from synovial membranes have a superior chondrogenesis capacity. Previous chondrogenic differentiation studies have used the total population of MSCs, including cells with several MSC markers, such as CD44, CD90, CD105, or CD73. However the chondrogenic capacity of an individual population of MSCs has not been examined. Our aim was to study the chondrogenic capacity of the cellular MSC subset, CD105(+), derived from synovial membrane tissues of patients with osteoarthritis (OA) and normal donors. The tissues were digested with a cocktail of collagenase/dispase and the isolated MSCs were seeded into plates. The subpopulation of CD105(+)-MSCs was separated using a magnetic separator. The MSCs were then differentiated towards chondrocyte-like cells using a specific medium to promote spheroid formation. Spheroids were collected after 14, 28, and 46 days in chondrogenic medium and stained with hematoxylin, eosin, Safranin O or Alcian blue to evaluate the extracellular matrix. Immunohistochemistry was performed to study collagen types I (COLI) and II (COLII) and aggrecan expression. Phenotypic characterization of the isolated CD105(+)-MSCs shows that these cells are also positive for CD90 and CD44, but negatives for CD34 and CD45. In addition, this cellular subset expressed Sox-9. Spheroids appeared after 7 days in culture in the presence of chondrogenic medium. Our studies show no differences between MSCs obtained from OA and normal synovial membranes during chondrogenesis. The morphological analysis of spheroids revealed characteristics typical of chondrocyte cells. The intensity of Safranin O, Alcian blue and aggrecan staining was positive and constant throughout the culture period. However, the intensity of COL2 staining was higher at 28 days (84.29 +/- 0.1 U) than at 46 days (61.28 +/- 01 U), while COL1 staining was not detected in any samples analyzed. These results were confirmed by reverse transcriptase-polymerase chain reaction assays. We conclude that the cellular subset of CD105(+)-MSCs has chondrogenic capacity. The study also show the similar chondrogenic capacity of CD105(+)-MSCs cultured from normal and OA synovial membranes. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544399     DOI: 10.1002/jcb.22238

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  29 in total

1.  Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties.

Authors:  Thomas J Bartosh; Joni H Ylöstalo; Arezoo Mohammadipoor; Nikolay Bazhanov; Katie Coble; Kent Claypool; Ryang Hwa Lee; Hosoon Choi; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

2.  Therapeutic potential of spheroids of stem cells from human exfoliated deciduous teeth for chronic liver fibrosis and hemophilia A.

Authors:  Yoshiaki Takahashi; Ratih Yuniartha; Takayoshi Yamaza; Soichiro Sonoda; Haruyoshi Yamaza; Kosuke Kirino; Koichiro Yoshimaru; Toshiharu Matsuura; Tomoaki Taguchi
Journal:  Pediatr Surg Int       Date:  2019-09-24       Impact factor: 1.827

3.  Unique characteristics of human mesenchymal stromal/progenitor cells pre-activated in 3-dimensional cultures under different conditions.

Authors:  Joni H Ylostalo; Thomas J Bartosh; April Tiblow; Darwin J Prockop
Journal:  Cytotherapy       Date:  2014-09-16       Impact factor: 5.414

Review 4.  "Ins" and "Outs" of mesenchymal stem cell osteogenesis in regenerative medicine.

Authors:  Dean T Yamaguchi
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

5.  Vascular remodeling underlies rebleeding in hemophilic arthropathy.

Authors:  Vikas Bhat; Merissa Olmer; Shweta Joshi; Donald L Durden; Thomas J Cramer; Richard Fw Barnes; Scott T Ball; Tudor H Hughes; Mauricio Silva; James V Luck; Randy E Moore; Laurent O Mosnier; Annette von Drygalski
Journal:  Am J Hematol       Date:  2015-10-08       Impact factor: 10.047

6.  The influence of bone marrow- and synovium-derived mesenchymal stromal cells from osteoarthritis patients on regulatory T cells in co-culture.

Authors:  S Hagmann; T Gotterbarm; T Müller; A-M Baesig; S Gantz; T Dreher; P W Kämmerer; S Frank; F Zeifang; B Moradi
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

7.  Preparation of anti-inflammatory mesenchymal stem/precursor cells (MSCs) through sphere formation using hanging-drop culture technique.

Authors:  Thomas J Bartosh; Joni H Ylostalo
Journal:  Curr Protoc Stem Cell Biol       Date:  2014-02-06

8.  Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspase-dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1).

Authors:  Thomas J Bartosh; Joni H Ylöstalo; Nikolay Bazhanov; Jessica Kuhlman; Darwin J Prockop
Journal:  Stem Cells       Date:  2013-11       Impact factor: 6.277

9.  Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype.

Authors:  Joni H Ylöstalo; Thomas J Bartosh; Katie Coble; Darwin J Prockop
Journal:  Stem Cells       Date:  2012-10       Impact factor: 6.277

10.  Chondrogenic potential and anti-senescence effect of hypoxia on canine adipose mesenchymal stem cells.

Authors:  Jienny Lee; Jeong Su Byeon; Keum Sil Lee; Na-Yeon Gu; Gyeong Been Lee; Hee-Ryang Kim; In-Soo Cho; Sang-Ho Cha
Journal:  Vet Res Commun       Date:  2015-12-10       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.